Drug intelligence / Profile preview

SNG1153

Development stage: Unknown
Lead developer: Shenogen Pharma
Modality: Small Molecules
Administration: Oral

Overview

SNG1153 (also known as Fukelading) is a small molecule inhibitor developed by Beijing Shenogen Pharma Group. It is currently in Phase 1 clinical development for the treatment of liver carcinoma and lung cancer. The drug is specifically designed to target and inhibit lung cancer stem/progenitor cells, which are a subpopulation of tumor cells associated with chemoresistance, metastasis, and disease recurrence. SNG1153 is part of Shenogen's broader research program focusing on the modulation of the estrogen receptor alpha variant ERα36 and related signaling pathways, such as the IL-6/Jak2/Stat3 axis, to suppress tumor growth and stemness in solid malignancies.

Other names: 氟可拉定Fukelading

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)NF-κBCXCR4 (C-X-C motif chemokine receptor 4)ERα36 (ER-alpha36)CTNNB1 (Beta-catenin)Breakpoint cluster region-Abelson tyrosine-protein kinase 1 Tyr177–Growth factor receptor-bound protein 2 signaling complex (BCR-ABL Tyr177–GRB2 signaling complex)

Beyond the preview

Go deeper on SNG1153.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNG1153.

Explore the full profile